Trial Profile
A PHASE 1, NON-RANDOMIZED, OPEN-LABEL, SINGLE DOSE STUDY TO EVALUATE THE EFFECT OF RENAL IMPAIRMENT ON THE PHARMACOKINETICS, SAFETY AND TOLERABILITY OF RIVIPANSEL (PF-06460031) IN SUBJECTS WITH RENAL IMPAIRMENT AND IN HEALTHY SUBJECTS
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 12 May 2020
Price :
$35
*
At a glance
- Drugs Rivipansel (Primary)
- Indications Sickle cell anaemia
- Focus Adverse reactions; Pharmacokinetics
- Sponsors GlycoMimetics
- 04 Dec 2018 Results presented at the 60th Annual Meeting and Exposition of the American Society of Hematology
- 05 Mar 2018 Status changed from recruiting to completed.
- 22 Feb 2018 Planned End Date changed from 1 Feb 2018 to 21 Feb 2018.